Characteristics of the 341 participants from whom a pre- and post-HCT MRD specimen was successfully analyzed, according to the conditioning regimen received
| Characteristic . | All participants . | RIC . | MAC . |
|---|---|---|---|
| n (%) | N = 341 | 138 (40.5) | 203 (59.5) |
| Age, median, y | 53 | 61 | 46 |
| Time from pre-HCT MRD specimen collection to HCT, median, d | 18 | 19 | 18 |
| Time from HCT to collection of post-MRD specimen, median, d | 42 | 41 | 44 |
| Time from HCT to randomization (start of placebo or gilteritinib), median (interquartile range), d | 57 (43-76) | 54 (43-71) | 61 (44-79) |
| Geographic distribution, n (%) | |||
| North America | 146 (42.8) | 70 (50.7) | 76 (37.4) |
| Europe | 87 (25.5) | 42 (30.4) | 45 (22.2) |
| Asia/rest of world | 108 (31.7) | 26 (18.8) | 82 (40.4) |
| Characteristic . | All participants . | RIC . | MAC . |
|---|---|---|---|
| n (%) | N = 341 | 138 (40.5) | 203 (59.5) |
| Age, median, y | 53 | 61 | 46 |
| Time from pre-HCT MRD specimen collection to HCT, median, d | 18 | 19 | 18 |
| Time from HCT to collection of post-MRD specimen, median, d | 42 | 41 | 44 |
| Time from HCT to randomization (start of placebo or gilteritinib), median (interquartile range), d | 57 (43-76) | 54 (43-71) | 61 (44-79) |
| Geographic distribution, n (%) | |||
| North America | 146 (42.8) | 70 (50.7) | 76 (37.4) |
| Europe | 87 (25.5) | 42 (30.4) | 45 (22.2) |
| Asia/rest of world | 108 (31.7) | 26 (18.8) | 82 (40.4) |